Literature DB >> 17540672

In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.

Joon Young Song1, Sae Yoon Kee, In Sook Hwang, Yu Bin Seo, Hye Won Jeong, Woo Joo Kim, Hee Jin Cheong.   

Abstract

OBJECTIVES: To determine the in vitro activities and interactions of imipenem, colistin and tigecycline with old antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
METHODS: Forty-three carbapenem-resistant A. baumannii isolates from the intensive care unit of a university hospital were collected and their MICs of imipenem, colistin and tigecycline were determined. With eight randomly selected carbapenem-resistant isolates, an in vitro time-kill study was performed for the evaluation of antibacterial activity of colistin, tigecycline, imipenem/sulbactam and colistin/rifampicin.
RESULTS: The time-kill study of colistin demonstrated bactericidal activity against A. baumannii at concentrations of 4xMIC and 8xMIC, whereas tigecycline showed bacteriostatic activity at all concentrations. The combination regimens of imipenem/sulbactam and colistin/rifampicin were synergistic and bactericidal at 1xMIC.
CONCLUSIONS: Imipenem/sulbactam combination, colistin and tigecycline showed good in vitro activities against carbapenem-resistant A. baumannii isolates. Even though colistin is bactericidal against carbapenem-resistant A. baumannii, the colistin/rifampicin combination is more warranted in order to be certain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540672     DOI: 10.1093/jac/dkm136

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

Review 1.  Polymyxins revisited.

Authors:  David Landman; Claudiu Georgescu; Don Antonio Martin; John Quale
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 2.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

3.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

4.  Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.

Authors:  G Kalin; E Alp; A Akin; R Coskun; M Doganay
Journal:  Infection       Date:  2013-07-05       Impact factor: 3.553

5.  Investigation of in-vitro susceptibility of multidrug-resistant Acinetobacter baumannii strains isolated from clinical specimens to tigecycline.

Authors:  Tekin Tas; Esra Kocoglu; Zafer Mengeloglu; Ozlem Bucak; Seyda Karabörk
Journal:  Bosn J Basic Med Sci       Date:  2013-11       Impact factor: 3.363

Review 6.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

Review 7.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 8.  Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

Authors:  Drosos E Karageorgopoulos; Theodore Kelesidis; Iosif Kelesidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2008-04-24       Impact factor: 5.790

9.  In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem.

Authors:  Louise M Oleksiuk; M Hong Nguyen; Ellen G Press; Cassaundra L Updike; Jessica A O'Hara; Yohei Doi; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

10.  Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients.

Authors:  Ryan K Shields; Cornelius J Clancy; Louise M Gillis; Eun J Kwak; Fernanda P Silveira; Rima C Abdel Massih; Gregory A Eschenauer; Brian A Potoski; M Hong Nguyen
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.